A practical reference on MC1R: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-19. Anything still debated is marked as such rather than presented as settled.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
== Further reading == Alsalim W, Fadel M (July 2003). "Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Oral methionine compared with intravenous N-acetyl cysteine for paracetamol overdose". Emerg Med J. 20 (4): 366–7. doi:10.1136/emj.20.4.366. PMC 1726135. PMID 12835357. van de Straat R, de Vries J, Debets AJ, Vermeulen NP (July 1987). "The mechanism of prevention of paracetamol-induced hepatotoxicity by 3,5-dialkyl substitution. The roles of glutathione depletion and oxidative stress". Biochem. Pharmacol. 36 (13): 2065–70. doi:10.1016/0006-2952(87)90132-8. PMID 3606627.
==== MeSH E05.200.750 – histological techniques ==== MeSH E05.200.750.132 – autoradiography MeSH E05.200.750.210 – bone demineralization technique MeSH E05.200.750.288 – decalcification technique MeSH E05.200.750.551 – histocytochemistry MeSH E05.200.750.551.512 – immunohistochemistry MeSH E05.200.750.551.512.240 – fluorescent antibody technique MeSH E05.200.750.551.512.240.300 – fluorescent antibody technique, direct MeSH E05.200.750.551.512.240.310 – fluorescent antibody technique, indirect MeSH E05.200.750.551.790 – periodic acid-schiff reaction MeSH E05.200.750.551.810 – prussian blue reaction MeSH E05.200.750.600 – histocytological preparation techniques MeSH E05.200.750.600.520 – microdissection MeSH E05.200.750.600.530 – microtomy MeSH E05.200.750.600.530.160 – cryoultramicrotomy MeSH E05.200.750.600.530.160.260 – frozen sections MeSH E05.200.750.600.620 – replica techniques MeSH E05.200.750.600.620.150 – corrosion casting MeSH E05.200.750.600.620.260 – freeze fracturing MeSH E05.200.750.600.620.260.400 – freeze etching MeSH E05.200.750.600.670 – staining and labeling MeSH E05.200.750.600.670.130 – chromosome banding MeSH E05.200.750.600.670.325 – in situ hybridization MeSH E05.200.750.600.670.325.350 – in situ hybridization, fluorescence MeSH E05.200.750.600.670.325.350.125 – chromosome painting MeSH E05.200.750.600.670.325.680 – primed in situ labeling MeSH E05.200.750.600.670.520 – negative staining MeSH E05.200.750.600.670.620 – periodic acid-schiff reaction MeSH E05.200.750.600.670.660 – prussian blue reaction MeSH E05.200.750.600.670.770 – shadowing (histology) MeSH E05.200.750.600.670.780 – silver staining MeSH E05.200.750.600.720 – tissue embedding MeSH E05.200.750.600.720.610 – paraffin embedding MeSH E05.200.750.600.720.640 – plastic embedding MeSH E05.200.750.600.760 – tissue preservation MeSH E05.200.750.600.760.160 – cryopreservation MeSH E05.200.750.600.760.160.260 – freeze drying MeSH E05.200.750.600.760.160.260.270 – freeze substitution MeSH E05.200.750.600.760.720 – tissue fixation
S. aureus: 0.25 μg/mL to 4.0 μg/mL S. aureus (methicillin resistant or MRSA): 1 μg/mL to 138 μg/mL S. epidermidis: ≤0.12 μg/mL to 6.25 μg/mL Although once described as narrow-spectrum, numerous studies have now shown that vancomycin decreases the levels of a wide spectrum of bacteria, including members of the Gram-negative Bacteroidota that are important in the human gut.
Tianeptine/naloxone (developmental code names TNX-601, TNX-601-CR, TNX-601-ER), or naloxone/tianeptine, is an extended-release combination of tianeptine, an atypical μ-opioid receptor agonist, and naloxone, an orally inactive μ-opioid receptor antagonist, which was under development for the treatment of major depressive disorder, post-traumatic stress disorder (PTSD), and neurocognitive dysfunction associated with corticosteroid use but was never marketed. Whereas tianeptine is marketed widely throughout Europe, Asia, and Latin America but is not available in the United States or the United Kingdom, tianeptine/naloxone was under development for registration in the United States and other countries. In addition, whereas tianeptine has a short duration of action and requires administration three times per day, tianeptine/naloxone was developed as an extended-release formulation with enhanced pharmacokinetics suitable for once-daily administration. The combination formulation employs tianeptine as the oxalate salt, which is said to have improved physicochemical properties for use in the extended-release formulation compared to the amorphous tianeptine sodium that is used in immediate-release tianeptine-only formulations. Naloxone is used in misuse-resistant oral drug formulations as it is inactive if taken orally but becomes active if oral tablets are crushed and administered parenterally, such as by injection.
==== Therapeutic treatments ==== D-amino acid oxidase is used in therapeutic treatments such as regulation of hormones, regulation of hypertension, treatment of schizophrenia, treatment of psychiatric and cognitive disorders, and possible pain reduction. Changing the amount of D-amino acid oxidase transporters with the use of drugs has therapeutic effects on schizophrenia. D-amino acid oxidase regulates D-aspartate, which regulates the secretion of melatonin, prolactin, testosterone, luteinizing hormone and growth hormone. By regulating D-amino acid oxidase, D-aspartate can also be regulated and control hormone secretion. Increased D-amino acid oxidase activity has been correlated with psychiatric and cognitive disorders, so reducing D-amino acid oxidase can have therapeutic effects on these disorders. D-amino acid oxidase helps produce L-6-hydroxynorleucine, which then generates omapatrilat. Omapatrilat inhibits angiotensin-converting enzyme and neutral endopeptidase and effectively reduces hypertension. D-amino acid oxidase also may have an effect on pain stimuli, but it is not confirmed yet.
Sources: en.wikipedia.org
Clinically used antipsychotic medications are listed below by drug group. Trade names appear in parentheses. A 2013 review has stated that the division of antipsychotics into first and second generation is perhaps not accurate. Notes: † indicates drugs that are no longer (or were never) marketed in English-speaking countries. ‡ denotes drugs that are no longer (or were never to begin with) marketed in the United States. Some antipsychotics are not firmly placed in either first-generation or second-generation classes. # denotes drugs that have been withdrawn worldwide.
=== Hypothalamic–hypophyseal portal system === Dopamine released at TIDA terminals enters the long portal veins and is delivered directly to lactotrophs of the anterior pituitary. An additional source of dopamine reaches the anterior lobe from the neurointermediate lobe via short portal vessels. Severing or compressing the pituitary stalk eliminates dopamine delivery and causes prolactin levels to rise sharply, an effect opposite to that seen with every other anterior pituitary hormone.
==== FAST ==== Fusion-associated small transmembrane proteins (FAST) are the smallest type of fusion protein. They are found in reoviruses, which are non-enveloped viruses and are specialized for cell-cell rather than virus-cell fusion, forming syncytia. They are the only known membrane fusion proteins found in non-enveloped viruses. They exploit the cell-cell adhesion machinery to achieve initial attachment. They might encourage fusion by inducing membrane curvature using a variety of hydrophobic motifs and modified residues.
The lungs are the primary organs of the respiratory system in many animals, including humans. In mammals and most other tetrapods, two lungs are located near the backbone on either side of the heart. Their function in the respiratory system is to extract oxygen from the atmosphere and transfer it into the bloodstream, and to release carbon dioxide from the bloodstream into the atmosphere, in a process of gas exchange. Respiration is driven by different muscular systems in different species. Mammals, reptiles and birds use their musculoskeletal systems to support and foster breathing. In early tetrapods, air was driven into the lungs by the pharyngeal muscles via buccal pumping, a mechanism still seen in amphibians. In humans, the primary muscle that drives breathing is the diaphragm. The lungs also provide airflow that makes vocalisation including speech possible. Humans have two lungs, a right lung and a left lung. They are situated within the thoracic cavity of the chest. The right lung is bigger than the left, and the left lung shares space in the chest with the heart. The lungs together weigh approximately 1.3 kilograms (2.9 lb), and the right is heavier. The lungs are part of the lower respiratory tract that begins at the trachea and branches into the bronchi and bronchioles, which receive air breathed in via the conducting zone. These divide until air reaches microscopic alveoli, where gas exchange takes place. Together, the lungs contain approximately 2,400 kilometers (1,500 mi) of airways and 300 to 500 million alveoli.
Sources: en.wikipedia.org
The analysis of the complete primary sequence of a protein using only one protease is usually not possible. In those cases the digestion of the target protein in several approaches with different enzymes is recommended. The resulting overlapping peptides permit the assembly of the complete sequence of the protein. For the digestion the proteins fixed in the matrix of the gel have to be made accessible for the protease. The permeation of the enzyme to the gel is believed to be facilitated by the dehydration of the gel pieces by treatment with acetonitrile and subsequent swelling in the digestion buffer containing the protease. This procedure relies on the presumption that the protease permeates to the gel by the process of swelling. Different studies about the penetration of the enzymes to the gel showed the process to be almost completely driven by diffusion. The drying of the gel does not seem to support the process. Therefore, the improvement of the in-gel digestion has to be achieved by the reduction of the way of the enzyme to its substrate e.g. by cutting the gel to pieces as small as possible. Usually, the in-gel digestion is run as an overnight process. For the use of trypsin as protease and a temperature of 37 °C the time of incubation found in most protocols is 12-15 h. However, experiments about the duration of the digestion process showed that after 3 h there is enough material for successful mass spectrometric analysis.
== Methods == Forensic chemists rely on a multitude of instruments to identify unknown substances found at a scene. Different methods can be used to determine the identity of the same substance, and it is up to the examiner to determine which method will produce the best results. Factors that forensic chemists might consider when performing an examination are the length of time a specific instrument will take to examine a substance and the destructive nature of that instrument. They prefer using nondestructive methods first, to preserve the evidence for further examination. Nondestructive techniques can also be used to narrow down the possibilities, making it more likely that the correct method will be used the first time when a destructive method is used.
White tried to use taking more pictures as an excuse to stay out longer, and McDivitt had to coax him in. He finally came back in after a total of approximately 23 minutes, almost 10 minutes later than was planned. He said: "It's the saddest moment of my life." By the time he got in, the spacecraft had entered darkness. The hatch proved to be as stubborn to relatch as it was to open. This would have been disastrous, resulting in both men's deaths on reentry. McDivitt was able to fix the mechanism once again, so White could close it, about 20 minutes after he got in. The mission plan called for opening the hatch again to throw out White's now-unnecessary EVA equipment, but McDivitt elected not to do this, instead keeping the unnecessary equipment on board for the rest of the flight. They powered down the spacecraft's maneuvering system, intending to drift for the next two-and-a-half days to conserve the remaining fuel. They also intended to sleep alternate four-hour periods, but this turned out to be extremely difficult with the constant radio communications and the small cabin, about the size of the front seats of a compact car. White's 20-minute space walk was the mission's highlight, with McDivitt's photographs being published worldwide. These also showed White wearing an Omega Speedmaster chronograph watch on his spacesuit sleeve, one of two makes which had been approved by NASA for space use following extensive tests. Omega were unaware of these tests or the fact that its product was going to be used in space, until the photos.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.